MayMag Biologics Announces Industrial-Scale FDA 506(e) Outsourcing Capabilities to Secure US Biologics Supply Chain for Healthcare Distributors

 Texas-based cGMP pharmaceutical manufacturer shifts paradigm from retail 503B compounding to large-scale, commercial production of FDA short-listed generic drugs and biosimilar biologics.

GARLAND, TX  — MayMag Biologics (formerly operating as Zeptide Pharma and Tirzepatide Pharma), a premier U.S.-based cGMP pharmaceutical manufacturer, today announced its expanded industrial capacity as a premier FDA-registered 506(e) outsourcing manufacturer. Purpose-built to address critical national drug shortages, MayMag Biologics provides commercial-scale supply chain redundancy specifically engineered for healthcare distributors, wholesalers, and institutional purchasing networks.

Unlike traditional retail 503B compounding facilities that focus on small-batch hospital or clinical office stock, MayMag Biologics operates strictly at an industrial 506(e) scale. Under Section 506(e) of the Federal Food, Drug, and Cosmetic Act, MayMag Biologics specializes in high-volume, commercial-grade production of sterile injectable biologics and generic medicines listed on the FDA Drug Shortage database.

Reinforcing the U.S. Drug Supply Chain

National healthcare distributors face persistent supply chain fragility across key therapeutic categories. MayMag Biologics addresses these vulnerabilities by delivering commercial-scale supply redundancy across critical short-listed drugs, including:

  • GLP-1 Biologics & Diabetes Care: Large-scale formulation and batch filling of cGMP GLP-1 receptor agonists and insulin analogs.

  • Auto-Injector & Emergency Delivery: In-house 510(k) auto-injector device integration, including emergency epinephrine auto-injectors and rheumatoid arthritis delivery systems.

  • Ophthalmic & Inhalation Therapeutics: High-purity sterile glaucoma treatments and specialized inhalation formulations.

  • Essential Multi-Dose Diluents: High-volume commercial manufacturing of Bacteriostatic Water for Injection (BWFI) with 0.9% benzyl alcohol preservatives.

Quality Assurance & Device Continuity

Operating out of state-of-the-art facilities in Texas, MayMag Biologics maintains strict adherence to cGMP, ISO 13485, and USP <797>/<800> quality control frameworks. The company operates with clean FDA Form 483 records and zero warning letters, ensuring that wholesale healthcare distributors receive consistent, batch-to-batch stability and device continuity.

"Healthcare distributors need more than localized compounders when critical drugs enter shortage status—they need reliable, commercial-scale manufacturing partners who understand batch stability, auto-device integration, and long-term supply redundancy," said a spokesperson for MayMag Biologics. "As an industrial 506(e) manufacturer, our sole focus is delivering bulk biosimilars and shortage-mitigating generics directly into the distribution channels that power American healthcare."

MayMag Biologics invites regional and national pharmaceutical distributors, hospital group purchasing organizations (GPOs), and contract development partners to validate its FDA credentials and explore contract manufacturing capabilities.

About MayMag Biologics

MayMag Biologics is an FDA-registered 506(e) industrial pharmaceutical manufacturer headquartered in Texas. Specializing in commercial-scale sterile injectables, biosimilars, and auto-injector drug delivery systems, MayMag Biologics serves as a trusted domestic supply chain partner for FDA short-listed medications. For more information, validation credentials, or catalog inquiries, visit maymagbiologics.com or peptidences.com.

Media & Distribution Inquiries:

MayMag Biologics Commercial CDMO Division

Email: cdmo@tirzepatidepharm.com


Website: maymagbiologics.com

Comments

Popular posts from this blog

FDA approved Biosimilar Injectable Biologics Contract Manufacturer in USA-MayMag Biologics

Mastering Parenteral Delivery: Technical Excellence in GLP-1 and Insulin Device CDMO Services

Scaling Parenteral Drug Delivery: Why Next-Gen Biologics Demand a Specialized Device CDMO